X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer

Phase 2 Unknown 300 enrolled Peking Union Medical College Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

Our study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of single X versus placebo as adjuvant chemotherapy regimens for elder breast cancer patients.

Timeline

Start: 2014-01
Primary completion: 2020-01
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Capecitabine	Small molecule	1250 mg/m2	Oral

X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer

Summary

Timeline

Drugs

Indications